Differential Diagnoses for Heart Failure with Reduced Ejection Fraction
The differential diagnosis for HFrEF (LVEF ≤40%) centers on identifying the underlying etiology causing myocardial dysfunction, with ischemic heart disease being the most common and critical cause to rule out, followed by non-ischemic cardiomyopathies, valvular disease, and tachyarrhythmias 1, 2.
Primary Etiologic Categories
Ischemic Cardiomyopathy
- Coronary artery disease is the predominant cause of HFrEF and must be actively excluded in any patient with new-onset reduced ejection fraction 1
- Look for: history of myocardial infarction, angina, coronary revascularization, or cardiovascular risk factors (diabetes, hypertension, smoking, hyperlipidemia)
- Patients with HFrEF have significantly higher rates of prior myocardial infarction compared to other HF phenotypes 3
Non-Ischemic Cardiomyopathies
The pathophysiology involves a significant initial myocardial insult triggering maladaptive remodeling processes 4:
- Dilated cardiomyopathy (idiopathic, familial/genetic, viral myocarditis)
- Toxic cardiomyopathy (alcohol, chemotherapy agents, cocaine, amphetamines)
- Infiltrative diseases (amyloidosis, sarcoidosis, hemochromatosis)
- Peripartum cardiomyopathy
- Stress-induced (Takotsubo) cardiomyopathy
Chronic Pressure/Volume Overload States
These represent chronically abnormal loading conditions that lead to progressive ventricular dysfunction 4:
- Valvular heart disease: aortic stenosis, aortic regurgitation, mitral regurgitation (note: HFrEF patients have higher rates of valvular disease than HFpEF patients 3)
- Chronic uncontrolled hypertension (though more commonly associated with HFpEF, can progress to HFrEF)
- Congenital heart disease with volume overload (atrial/ventricular septal defects)
Arrhythmia-Induced Cardiomyopathy
- Tachycardia-induced cardiomyopathy from chronic atrial fibrillation, atrial flutter, or ventricular tachycardia
- Sustained tachyarrhythmias can cause reversible ventricular dysfunction if rate control is achieved
Inflammatory/Infectious
- Acute myocarditis (viral, autoimmune, drug-induced)
- Myopericarditis 5
- Chagas disease (in endemic regions)
Key Diagnostic Distinctions
Structural and Functional Characteristics
According to the 2022 AHA/ACC/HFSA guidelines, HFrEF is defined as LVEF ≤40% with evidence of structural heart disease 5. Echocardiography in HFrEF typically shows:
- Greater left ventricular dilation
- Significant systolic dysfunction
- Progressive adverse cardiac remodeling 2, 3
Biomarker Patterns
- NT-proBNP, troponin, and CRP levels are significantly higher in HFrEF compared to HFpEF 3
- Elevated natriuretic peptides above age-specific thresholds support the diagnosis 2
Critical Pitfalls to Avoid
Failing to identify ischemic etiology: Cardiac ischemia must be considered in any patient with new-onset HFrEF as it has specific treatment implications (revascularization) 1
Missing reversible causes: Tachycardia-induced cardiomyopathy, alcohol-induced cardiomyopathy, and certain toxic exposures are potentially reversible if identified early
Overlooking HFmrEF trajectory: Patients with LVEF 41-49% (HFmrEF) may be on a dynamic trajectory—either improving from previous HFrEF or deteriorating toward HFrEF. One EF measurement at one time point is inadequate; evaluate the trajectory over time 5, 6
Confusing HFrEF with HFpEF: While clinical presentations overlap, HFpEF patients are typically older, more often female, with higher rates of hypertension, atrial fibrillation, and obesity, whereas HFrEF patients more frequently have prior MI and valvular disease 3
Pathophysiologic Framework
The underlying mechanisms involve a reactive cascade where the initial insult leads to reduced cardiac output, triggering systemic neurohormonal activation (RAAS, sympathetic nervous system), peripheral vascular effects, and localized cardiac substrate changes with progressive adverse remodeling 4. HFrEF typically demonstrates a relatively coherent pathophysiological architecture with mutually reinforcing processes including neurohormonal activation, calcium metabolism disturbances, mitochondrial dysfunction, and extracellular matrix remodeling 6.